A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.
This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.
• Signed informed consent prior to any study-mandated procedure;
• Patients aged over 18 years old;
• All women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment.
• Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
• Diagnosed with brain metastasis of colorectal origin and scheduled for a resection.